Objective: To describe the incidence and severity of infusion-related adverse events of mesenchymal stem cells (MSC) for Parkinson’s disease in patients who underwent treatment.

Background: Cell-based therapy has emerged as an innovative method of treatment for neurodegenerative diseases, including Parkinson’s disease. With their relative ease of expansion, and lack of significant immunogenicity, MSCs may be a potential treatment option for these patients.

Methods: Medical records of 11 previously diagnosed Parkinson’s disease patients who were given intravenous and/or intraspinal infusions of minimally manipulated autologous bone marrow-derived MSCs were reviewed. Demographic and clinical data were obtained. Any infusion-related adverse effects were reported.

Results: Patients received between 1and 10 monthly infusions, with a mean of 6 infusions. Out of 66 total infusions, there was only 1 recorded instance of adverse event reported by the patient as non-disabling cervical pain, relieved by oral pain medications. Intravenous and intraspinal infusions were performed with no noted technical difficulty. One patient expired 1 year after his last dose, due to complications of Parkinson’s disease not related to mesenchymal stem cell infusion.

Conclusions: Intravenous and/or intraspinal infusion of bone marrow-derived autologous MSC therapy for Parkinson’s disease is safe, and is not associated with any significant infusion-related mortality or morbidity.

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/a-descriptive-study-on-the-safety-and-feasibility-of-mesenchymal-stem-cell-therapy-for-parkinsons-disease-a-case-series/